Shuchi Nahar's Weekend Blog!

  Your ultimate guide to understand the basics and details about the Indian Pharma Sector A Brief Understanding On Pharma Sector From Its Key Terms To Its Filing And Procedures. The following article is on the Indian Pharmaceutical Industry, the article is written to familiarize ourselves with the terminology or the jargon’s of the pharmaceutical industry. It will briefly touch upon terms like API, Intermediates, CDMO’s/ CRAM’s, PARA Filings,  Innovator drug, Generic drugs, life cycle development etc. The Indian pharmaceuticals market has characteristics that make it unique. First, branded generics dominate, making up for 70 to 80% of the retail market.  India also has the feather of being the  largest exporter of generic drugs  in the world.  Second, local players have enjoyed a dominant position driven by the formulation development capabilities and early investments.  Third, price levels are low, driven by intense competition. While India ranks tenth globally in terms of value, it

  Laurus Labs Ltd. –Story of Patience, diligence, and perseverance Twitter Handle: @shuchi_nahar Link to Company Overview of Laurus Labs in detail: https://myweekendspot.blogspot.com/2020/09/laurus-labs-company-overview.html Result Update – Q3FY21 Laurus Lab performed extremely well consecutive in the 3 rd  quarter of FY21. The company did a robust growth in all three segments. Having   a healthy order book for FY 21 & beyond in FDF CMO business with a strategic partner in EU. Consolidated revenue for the quarter increased by 76% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 273 Crs. for the quarter. The generic API division recorded a healthy growth of over 100% for the quarter, the growth was led by higher growth in ARV API business in turn led by higher volume of 1st line products. The Formulations business showcased a growth of over 120% for the 9M period, led by higher LMIC bus

Important Segments to track growth for Pharma Companies Shuchi.P.Nahar Investments in the global pharmaceuticals sector to increase to over $1,400 billion over the next three years, driven by a number of new medicines. With healthy R&D spending going forward, the Contract Research and Manufacturing (CRAMS) segment offers growth opportunities to Indian companies .  Change in regulations around generic approvals will help Indian companies to increase penetration in Chinese markets, which will improve margin expansion.  What are CRAMS ?  CRAMS is defined as the process of outsourcing research services/ product manufacturing activities to organizations which can provide the service at a low cost. CRAMS basically consists of the following two activities: contract research and contract manufacturing. CRAMS is mainly used in the Pharmaceutical and Biotechnology sectors that require extensive R&D and large-scale manufacturing facilities. It is expected that the demand for c

Growth Outlook of Pharmaceutical Sector! Key Points to Know. SHUCHI.P.NAHAR The Indian market is impossible to ignore, given its economic prospects. Foreign companies view India as a potential significant contributor of future sales and are ramping up their investments in the country accordingly. India’s domestic market looks promising for global pharma looking to launch new products.  The country’s growing capabilities in contract manufacturing, R&D and clinical trials also make it a preferred outsourcing partner for global pharma at every stage of the value chain. So what strategy should foreign pharmaceutical companies eager to enter the country or expand their existing operations adopt?   The growth trajectory for the Indian pharmaceutical industry is likely to remain at 10-13 percent in 2020-21 despite challenges, according to rating agency ICRA. The expected growth in the next financial year is on the back of healthy demand from the domestic market given incre

Pharma Sector uptrend 2020 Shuchi. P. Nahar Road to 2020 As the industry embarks on its road to 2020, it has taken a giant leap in understanding the newer technologies of genomics, proteonomics, etc., which have led to the production of new medicines, diagnostic tools and lines of research. However, there is still a lot to learn about the human body and even better things lie ahead. Companies will have to re-evaluate their product portfolio, pipeline and development strategy. They will need to revise their budgeting and forecasting processes, billing and payment systems, and almost everything about the way they have been going to the market. We believe there are a number of things companies can do to equip themselves for the journey to 2020 and increase their chances of reaching the end of the road in a good shape.The Indian pharmaceutical industry has contributed immensely not just to Indian but to global healthcare outcomes. India continues to play a material role in manuf